▶ 調査レポート

初代肝細胞の世界市場2023年:ヒト初代細胞、動物初代細胞

• 英文タイトル:Global Primary Hepatocytes Market Research Report 2023

QYResearchが調査・発行した産業分析レポートです。初代肝細胞の世界市場2023年:ヒト初代細胞、動物初代細胞 / Global Primary Hepatocytes Market Research Report 2023 / MRC23Q38309資料のイメージです。• レポートコード:MRC23Q38309
• 出版社/出版日:QYResearch / 2023年3月
• レポート形態:英文、PDF、120ページ
• 納品方法:Eメール(2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥406,000 (USD2,900)▷ お問い合わせ
  Enterprise License¥812,000 (USD5,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは世界の初代肝細胞市場について調査・分析し、世界の初代肝細胞市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析(ヒト初代細胞、動物初代細胞)、用途別セグメント分析(ライフサイエンス研究企業、研究機関、その他)、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Thermo Fisher Scientific, Inc.、Merck KGaA、Lonza、Cell Biologics, Inc.、PromoCell GmbH、HemaCare Corporation、ZenBio, Inc.、STEMCELL Technologies, Inc.、Corning Incorporated、AllCells、Axol Bioscience Ltd.、iXCells Biotechnologies、Neuromics、StemExpress、BioIVT、ScienCell Research Laboratories, Inc.、PPA Research Group, Inc.、Creative Bioarray、BPS Bioscience, Inc.、Epithelix Sàrl、ReachBio LLC、AcceGen、Sekisui XenoTech, LLC、Biopredic Internationalなどが含まれています。世界の初代肝細胞市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、初代肝細胞市場規模を推定する際に考慮しました。本レポートは、初代肝細胞の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、初代肝細胞に関するビジネス上の意思決定に役立てることを目的としています。

・初代肝細胞市場の概要
- 製品の定義
- 初代肝細胞のタイプ別セグメント
- 世界の初代肝細胞市場規模:タイプ別分析(ヒト初代細胞、動物初代細胞)
- 初代肝細胞の用途別セグメント
- 世界の初代肝細胞市場規模:用途別分析(ライフサイエンス研究企業、研究機関、その他)
- 世界の初代肝細胞市場規模予測(2018年-2029年)
- 初代肝細胞の平均価格推移(2018年-2029年)
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 初代肝細胞市場の競争状況およびトレンド

・初代肝細胞の地域別市場規模
- 北米の初代肝細胞市場規模(2018年-2029年)
- アメリカの初代肝細胞市場規模(2018年-2029年)
- ヨーロッパの初代肝細胞市場規模(2018年-2029年)
- アジア太平洋の初代肝細胞市場規模(2018年-2029年)
- 中国の初代肝細胞市場規模(2018年-2029年)
- 日本の初代肝細胞市場規模(2018年-2029年)
- 韓国の初代肝細胞市場規模(2018年-2029年)
- インドの初代肝細胞市場規模(2018年-2029年)
- オーストラリアの初代肝細胞市場規模(2018年-2029年)
- 中南米の初代肝細胞市場規模(2018年-2029年)
- 中東・アフリカの初代肝細胞市場規模(2018年-2029年)

・タイプ別セグメント:ヒト初代細胞、動物初代細胞
- 世界の初代肝細胞のタイプ別販売量(2018年-2023年)
- 世界の初代肝細胞のタイプ別売上(2018年-2023年)
- 世界の初代肝細胞のタイプ別価格

・用途別セグメント:ライフサイエンス研究企業、研究機関、その他
- 世界の初代肝細胞の用途別販売量(2018年-2023年)
- 世界の初代肝細胞の用途別売上(2018年-2023年)
- 世界の初代肝細胞の用途別価格

・主要企業のプロファイル:企業情報、事業概要、売上、製品ポートフォリオ、動向
Thermo Fisher Scientific, Inc.、Merck KGaA、Lonza、Cell Biologics, Inc.、PromoCell GmbH、HemaCare Corporation、ZenBio, Inc.、STEMCELL Technologies, Inc.、Corning Incorporated、AllCells、Axol Bioscience Ltd.、iXCells Biotechnologies、Neuromics、StemExpress、BioIVT、ScienCell Research Laboratories, Inc.、PPA Research Group, Inc.、Creative Bioarray、BPS Bioscience, Inc.、Epithelix Sàrl、ReachBio LLC、AcceGen、Sekisui XenoTech, LLC、Biopredic International

・産業チェーンと販売チャネルの分析
- 初代肝細胞産業チェーン分析
- 初代肝細胞の主要原材料
- 初代肝細胞の販売チャネル
- 初代肝細胞のディストリビューター
- 初代肝細胞の主要顧客

・初代肝細胞市場ダイナミクス
- 初代肝細胞の業界動向
- 初代肝細胞市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Primary Hepatocytes market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Primary Hepatocytes is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Primary Hepatocytes is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Primary Hepatocytes include Thermo Fisher Scientific, Inc., Merck KGaA, Lonza, Cell Biologics, Inc., PromoCell GmbH, HemaCare Corporation, ZenBio, Inc., STEMCELL Technologies, Inc. and Corning Incorporated, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Hepatocytes, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Hepatocytes.
The Primary Hepatocytes market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Primary Hepatocytes market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Hepatocytes manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Thermo Fisher Scientific, Inc.
Merck KGaA
Lonza
Cell Biologics, Inc.
PromoCell GmbH
HemaCare Corporation
ZenBio, Inc.
STEMCELL Technologies, Inc.
Corning Incorporated
AllCells
Axol Bioscience Ltd.
iXCells Biotechnologies
Neuromics
StemExpress
BioIVT
ScienCell Research Laboratories, Inc.
PPA Research Group, Inc.
Creative Bioarray
BPS Bioscience, Inc.
Epithelix Sàrl
ReachBio LLC
AcceGen
Sekisui XenoTech, LLC
Biopredic International
Segment by Type
Human Primary Cells
Animal Primary Cells
Segment by Application
Life Science Research Companies
Research Institutes
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Primary Hepatocytes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Primary Hepatocytes in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

レポート目次

1 Primary Hepatocytes Market Overview
1.1 Product Overview and Scope of Primary Hepatocytes
1.2 Primary Hepatocytes Segment by Type
1.2.1 Global Primary Hepatocytes Market Value Comparison by Type (2023-2029)
1.2.2 Human Primary Cells
1.2.3 Animal Primary Cells
1.3 Primary Hepatocytes Segment by Application
1.3.1 Global Primary Hepatocytes Market Value by Application: (2023-2029)
1.3.2 Life Science Research Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Global Primary Hepatocytes Market Size Estimates and Forecasts
1.4.1 Global Primary Hepatocytes Revenue 2018-2029
1.4.2 Global Primary Hepatocytes Sales 2018-2029
1.4.3 Global Primary Hepatocytes Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Primary Hepatocytes Market Competition by Manufacturers
2.1 Global Primary Hepatocytes Sales Market Share by Manufacturers (2018-2023)
2.2 Global Primary Hepatocytes Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Primary Hepatocytes Average Price by Manufacturers (2018-2023)
2.4 Global Primary Hepatocytes Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Primary Hepatocytes, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Hepatocytes, Product Type & Application
2.7 Primary Hepatocytes Market Competitive Situation and Trends
2.7.1 Primary Hepatocytes Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary Hepatocytes Players Market Share by Revenue
2.7.3 Global Primary Hepatocytes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Hepatocytes Retrospective Market Scenario by Region
3.1 Global Primary Hepatocytes Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Primary Hepatocytes Global Primary Hepatocytes Sales by Region: 2018-2029
3.2.1 Global Primary Hepatocytes Sales by Region: 2018-2023
3.2.2 Global Primary Hepatocytes Sales by Region: 2024-2029
3.3 Global Primary Hepatocytes Global Primary Hepatocytes Revenue by Region: 2018-2029
3.3.1 Global Primary Hepatocytes Revenue by Region: 2018-2023
3.3.2 Global Primary Hepatocytes Revenue by Region: 2024-2029
3.4 North America Primary Hepatocytes Market Facts & Figures by Country
3.4.1 North America Primary Hepatocytes Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Primary Hepatocytes Sales by Country (2018-2029)
3.4.3 North America Primary Hepatocytes Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Primary Hepatocytes Market Facts & Figures by Country
3.5.1 Europe Primary Hepatocytes Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Primary Hepatocytes Sales by Country (2018-2029)
3.5.3 Europe Primary Hepatocytes Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Hepatocytes Market Facts & Figures by Country
3.6.1 Asia Pacific Primary Hepatocytes Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Primary Hepatocytes Sales by Country (2018-2029)
3.6.3 Asia Pacific Primary Hepatocytes Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Primary Hepatocytes Market Facts & Figures by Country
3.7.1 Latin America Primary Hepatocytes Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Primary Hepatocytes Sales by Country (2018-2029)
3.7.3 Latin America Primary Hepatocytes Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Hepatocytes Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Hepatocytes Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Primary Hepatocytes Sales by Country (2018-2029)
3.8.3 Middle East and Africa Primary Hepatocytes Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Primary Hepatocytes Sales by Type (2018-2029)
4.1.1 Global Primary Hepatocytes Sales by Type (2018-2023)
4.1.2 Global Primary Hepatocytes Sales by Type (2024-2029)
4.1.3 Global Primary Hepatocytes Sales Market Share by Type (2018-2029)
4.2 Global Primary Hepatocytes Revenue by Type (2018-2029)
4.2.1 Global Primary Hepatocytes Revenue by Type (2018-2023)
4.2.2 Global Primary Hepatocytes Revenue by Type (2024-2029)
4.2.3 Global Primary Hepatocytes Revenue Market Share by Type (2018-2029)
4.3 Global Primary Hepatocytes Price by Type (2018-2029)
5 Segment by Application
5.1 Global Primary Hepatocytes Sales by Application (2018-2029)
5.1.1 Global Primary Hepatocytes Sales by Application (2018-2023)
5.1.2 Global Primary Hepatocytes Sales by Application (2024-2029)
5.1.3 Global Primary Hepatocytes Sales Market Share by Application (2018-2029)
5.2 Global Primary Hepatocytes Revenue by Application (2018-2029)
5.2.1 Global Primary Hepatocytes Revenue by Application (2018-2023)
5.2.2 Global Primary Hepatocytes Revenue by Application (2024-2029)
5.2.3 Global Primary Hepatocytes Revenue Market Share by Application (2018-2029)
5.3 Global Primary Hepatocytes Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific, Inc.
6.1.1 Thermo Fisher Scientific, Inc. Corporation Information
6.1.2 Thermo Fisher Scientific, Inc. Description and Business Overview
6.1.3 Thermo Fisher Scientific, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Thermo Fisher Scientific, Inc. Primary Hepatocytes Product Portfolio
6.1.5 Thermo Fisher Scientific, Inc. Recent Developments/Updates
6.2 Merck KGaA
6.2.1 Merck KGaA Corporation Information
6.2.2 Merck KGaA Description and Business Overview
6.2.3 Merck KGaA Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck KGaA Primary Hepatocytes Product Portfolio
6.2.5 Merck KGaA Recent Developments/Updates
6.3 Lonza
6.3.1 Lonza Corporation Information
6.3.2 Lonza Description and Business Overview
6.3.3 Lonza Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Lonza Primary Hepatocytes Product Portfolio
6.3.5 Lonza Recent Developments/Updates
6.4 Cell Biologics, Inc.
6.4.1 Cell Biologics, Inc. Corporation Information
6.4.2 Cell Biologics, Inc. Description and Business Overview
6.4.3 Cell Biologics, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cell Biologics, Inc. Primary Hepatocytes Product Portfolio
6.4.5 Cell Biologics, Inc. Recent Developments/Updates
6.5 PromoCell GmbH
6.5.1 PromoCell GmbH Corporation Information
6.5.2 PromoCell GmbH Description and Business Overview
6.5.3 PromoCell GmbH Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.5.4 PromoCell GmbH Primary Hepatocytes Product Portfolio
6.5.5 PromoCell GmbH Recent Developments/Updates
6.6 HemaCare Corporation
6.6.1 HemaCare Corporation Corporation Information
6.6.2 HemaCare Corporation Description and Business Overview
6.6.3 HemaCare Corporation Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.6.4 HemaCare Corporation Primary Hepatocytes Product Portfolio
6.6.5 HemaCare Corporation Recent Developments/Updates
6.7 ZenBio, Inc.
6.6.1 ZenBio, Inc. Corporation Information
6.6.2 ZenBio, Inc. Description and Business Overview
6.6.3 ZenBio, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ZenBio, Inc. Primary Hepatocytes Product Portfolio
6.7.5 ZenBio, Inc. Recent Developments/Updates
6.8 STEMCELL Technologies, Inc.
6.8.1 STEMCELL Technologies, Inc. Corporation Information
6.8.2 STEMCELL Technologies, Inc. Description and Business Overview
6.8.3 STEMCELL Technologies, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.8.4 STEMCELL Technologies, Inc. Primary Hepatocytes Product Portfolio
6.8.5 STEMCELL Technologies, Inc. Recent Developments/Updates
6.9 Corning Incorporated
6.9.1 Corning Incorporated Corporation Information
6.9.2 Corning Incorporated Description and Business Overview
6.9.3 Corning Incorporated Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Corning Incorporated Primary Hepatocytes Product Portfolio
6.9.5 Corning Incorporated Recent Developments/Updates
6.10 AllCells
6.10.1 AllCells Corporation Information
6.10.2 AllCells Description and Business Overview
6.10.3 AllCells Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.10.4 AllCells Primary Hepatocytes Product Portfolio
6.10.5 AllCells Recent Developments/Updates
6.11 Axol Bioscience Ltd.
6.11.1 Axol Bioscience Ltd. Corporation Information
6.11.2 Axol Bioscience Ltd. Primary Hepatocytes Description and Business Overview
6.11.3 Axol Bioscience Ltd. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Axol Bioscience Ltd. Primary Hepatocytes Product Portfolio
6.11.5 Axol Bioscience Ltd. Recent Developments/Updates
6.12 iXCells Biotechnologies
6.12.1 iXCells Biotechnologies Corporation Information
6.12.2 iXCells Biotechnologies Primary Hepatocytes Description and Business Overview
6.12.3 iXCells Biotechnologies Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.12.4 iXCells Biotechnologies Primary Hepatocytes Product Portfolio
6.12.5 iXCells Biotechnologies Recent Developments/Updates
6.13 Neuromics
6.13.1 Neuromics Corporation Information
6.13.2 Neuromics Primary Hepatocytes Description and Business Overview
6.13.3 Neuromics Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Neuromics Primary Hepatocytes Product Portfolio
6.13.5 Neuromics Recent Developments/Updates
6.14 StemExpress
6.14.1 StemExpress Corporation Information
6.14.2 StemExpress Primary Hepatocytes Description and Business Overview
6.14.3 StemExpress Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.14.4 StemExpress Primary Hepatocytes Product Portfolio
6.14.5 StemExpress Recent Developments/Updates
6.15 BioIVT
6.15.1 BioIVT Corporation Information
6.15.2 BioIVT Primary Hepatocytes Description and Business Overview
6.15.3 BioIVT Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.15.4 BioIVT Primary Hepatocytes Product Portfolio
6.15.5 BioIVT Recent Developments/Updates
6.16 ScienCell Research Laboratories, Inc.
6.16.1 ScienCell Research Laboratories, Inc. Corporation Information
6.16.2 ScienCell Research Laboratories, Inc. Primary Hepatocytes Description and Business Overview
6.16.3 ScienCell Research Laboratories, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.16.4 ScienCell Research Laboratories, Inc. Primary Hepatocytes Product Portfolio
6.16.5 ScienCell Research Laboratories, Inc. Recent Developments/Updates
6.17 PPA Research Group, Inc.
6.17.1 PPA Research Group, Inc. Corporation Information
6.17.2 PPA Research Group, Inc. Primary Hepatocytes Description and Business Overview
6.17.3 PPA Research Group, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.17.4 PPA Research Group, Inc. Primary Hepatocytes Product Portfolio
6.17.5 PPA Research Group, Inc. Recent Developments/Updates
6.18 Creative Bioarray
6.18.1 Creative Bioarray Corporation Information
6.18.2 Creative Bioarray Primary Hepatocytes Description and Business Overview
6.18.3 Creative Bioarray Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Creative Bioarray Primary Hepatocytes Product Portfolio
6.18.5 Creative Bioarray Recent Developments/Updates
6.19 BPS Bioscience, Inc.
6.19.1 BPS Bioscience, Inc. Corporation Information
6.19.2 BPS Bioscience, Inc. Primary Hepatocytes Description and Business Overview
6.19.3 BPS Bioscience, Inc. Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.19.4 BPS Bioscience, Inc. Primary Hepatocytes Product Portfolio
6.19.5 BPS Bioscience, Inc. Recent Developments/Updates
6.20 Epithelix Sàrl
6.20.1 Epithelix Sàrl Corporation Information
6.20.2 Epithelix Sàrl Primary Hepatocytes Description and Business Overview
6.20.3 Epithelix Sàrl Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Epithelix Sàrl Primary Hepatocytes Product Portfolio
6.20.5 Epithelix Sàrl Recent Developments/Updates
6.21 ReachBio LLC
6.21.1 ReachBio LLC Corporation Information
6.21.2 ReachBio LLC Primary Hepatocytes Description and Business Overview
6.21.3 ReachBio LLC Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.21.4 ReachBio LLC Primary Hepatocytes Product Portfolio
6.21.5 ReachBio LLC Recent Developments/Updates
6.22 AcceGen
6.22.1 AcceGen Corporation Information
6.22.2 AcceGen Primary Hepatocytes Description and Business Overview
6.22.3 AcceGen Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.22.4 AcceGen Primary Hepatocytes Product Portfolio
6.22.5 AcceGen Recent Developments/Updates
6.23 Sekisui XenoTech, LLC
6.23.1 Sekisui XenoTech, LLC Corporation Information
6.23.2 Sekisui XenoTech, LLC Primary Hepatocytes Description and Business Overview
6.23.3 Sekisui XenoTech, LLC Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Sekisui XenoTech, LLC Primary Hepatocytes Product Portfolio
6.23.5 Sekisui XenoTech, LLC Recent Developments/Updates
6.24 Biopredic International
6.24.1 Biopredic International Corporation Information
6.24.2 Biopredic International Primary Hepatocytes Description and Business Overview
6.24.3 Biopredic International Primary Hepatocytes Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Biopredic International Primary Hepatocytes Product Portfolio
6.24.5 Biopredic International Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Hepatocytes Industry Chain Analysis
7.2 Primary Hepatocytes Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Hepatocytes Production Mode & Process
7.4 Primary Hepatocytes Sales and Marketing
7.4.1 Primary Hepatocytes Sales Channels
7.4.2 Primary Hepatocytes Distributors
7.5 Primary Hepatocytes Customers
8 Primary Hepatocytes Market Dynamics
8.1 Primary Hepatocytes Industry Trends
8.2 Primary Hepatocytes Market Drivers
8.3 Primary Hepatocytes Market Challenges
8.4 Primary Hepatocytes Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer